NCT00019175View on ClinicalTrials.gov

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic Melanoma

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

August 31, 1996

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

aldesleukin

BIOLOGICAL

fowlpox virus vaccine vector

BIOLOGICAL

gp100 antigen

Trial Locations (1)

20892

Surgery Branch, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00019175 - Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic Melanoma | Biotech Hunter | Biotech Hunter